1999
The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Research 1999, 59: 1015-20. PMID: 10070957.Peer-Reviewed Original ResearchConceptsHealth Study cohortBreast cancer riskBreast cancerHormone levelsA2 alleleCancer riskNurses' Health Study cohortStrong independent risk factorA2/A2 genotypeCYP17 A2 alleleElevated levelsAdvanced breast cancerIncident breast cancerIndependent risk factorPolycystic ovarian syndromeCertain steroid hormonesA1/A1 genotypeCase-control studyPlasma hormone levelsSteroid hormone levelsLater agePremenopausal womenCYP17 genotypeHormone replacementOvarian syndrome
1998
Plasma Sex Steroid Hormone Levels and Risk of Breast Cancer in Postmenopausal Women
Hankinson S, Willett W, Manson J, Colditz G, Hunter D, Spiegelman D, Barbieri R, Speizer F. Plasma Sex Steroid Hormone Levels and Risk of Breast Cancer in Postmenopausal Women. Journal Of The National Cancer Institute 1998, 90: 1292-1299. PMID: 9731736, DOI: 10.1093/jnci/90.17.1292.Peer-Reviewed Original ResearchConceptsSex steroid hormone levelsHormone replacement therapyBreast cancer riskPostmenopausal womenBreast cancerSteroid hormone levelsBlood collectionEstrogen levelsReplacement therapyHormone levelsCancer riskHealth StudyPrevious hormone replacement therapyPlasma sex steroid hormone levelsPostmenopausal estrogen levelsNurses' Health StudyPlasma estrogen levelsLevels of estradiolCase-control studyPlasma androgen levelsBioavailable estradiolMenopausal statusSignificant positive associationControl subjectsLowest quartile